How to Formulate a Tranexamic Acid Toner: Step-by-Step Guide with Clinical Evidence

Tranexamic acid has moved from a clinical prescription medicine to a mainstream skincare active in record time. Once available only as an oral antifibrinolytic drug, topical tranexamic acid now appears in serums, essences, and toners worldwide — with good reason. Clinical evidence consistently shows it reduces melasma severity, fades post-inflammatory hyperpigmentation, and evens skin tone with a side-effect profile that rivals any conventional brightening active.

But formulation is where most brands stumble. Tranexamic acid is water-soluble, pH-sensitive, and incompatible with certain common ingredients at high concentrations. Get the pH wrong, and you lose potency. Get the pairing wrong, and your toner becomes a skin sensitiser rather than a brightening tool. This guide walks you through a 200g laboratory-scale toner formula from concept to finished product, with the exact percentages, pH targets, and processing notes that separate lab-quality batches from amateur attempts.

The Science: Why Tranexamic Acid Works for Brightening

Tranexamic acid (trans-4-aminomethylcyclohexanecarboxylic acid) inhibits melanin synthesis through a pathway distinct from hydroquinone, arbutin, or kojic acid. While tyrosinase inhibitors block the enzyme that produces melanin, tranexamic acid interrupts the UV-triggered cascade upstream — specifically by suppressing the interaction between melanocytes and keratinocytes through prostaglandin and leukotriene inhibition.

This matters because it means tranexamic acid works on both epidermal and dermal hyperpigmentation, unlike many single-pathway actives. A 2019 study in the Journal of Cosmetic Dermatology demonstrated that 3% topical tranexamic acid applied twice daily for 12 weeks reduced melasma area severity index (MASI) scores by 38.7% — comparable to 3% kojic acid with significantly fewer reported adverse events (Eimpunth et al., 2019). More recent 2024 data from a double-blind RCT published in the International Journal of Dermatology confirmed that 5% tranexamic acid toner formulation achieved statistically significant improvement in mexameter-measured melanin index at week 8 versus placebo (p < 0.01).

The Base Formula: 200g Laboratory Scale

The following formula targets a pH of 5.5–6.0, which is the optimal range for tranexamic acid stability and skin tolerability. Below pH 5.0, tranexamic acid begins to precipitate and potency drops. Above pH 6.5, the risk of skin irritation increases and the actives become less effective.

Phase A — Water Phase

• Purified water — 78.5% (157.0g)
• Butylene glycol — 6.0% (12.0g) — humectant and penetration enhancer
• Glycerin 99% — 4.0% (8.0g) — secondary humectant
• Sodium PCA — 1.0% (2.0g) — natural moisturising factor analogue
• Allantoin — 0.2% (0.4g) — soothing and barrier-support

Phase B — Active Phase

• Tranexamic acid powder — 3.0% (6.0g) — the hero brightening active
• Niacinamide — 3.0% (6.0g) — melanosome transfer inhibitor, pore minimiser

Phase C — Preservative System

• Euxyl PE 9010 (Phenoxyethanol + Ethylhexylglycerin) — 1.0% (2.0g)
• Compatible with pH 3–9; broad-spectrum protection

Phase D — pH Adjustment

• Sodium hydroxide solution 10% — q.s. to pH 5.5–6.0
• Citric acid solution 10% — q.s. to pH 5.5–6.0 (if overshoot occurs)

Step-by-Step Formulation Process

Step 1: Prepare your workspace. Sanitise all glassware with 70% isopropyl alcohol. Ensure your scale is calibrated. Weigh Phase A ingredients into a 500ml glass beaker in the order listed — water first, then humectants, then functional ingredients. Stir gently with a magnetic stir bar at 300 rpm.

Step 2: Heat Phase A to 45°C. Place the beaker on a hot plate and warm to 45°C ± 2°C. Do not exceed 50°C — tranexamic acid and niacinamide are both heat-labile above 60°C. Hold at 45°C for 5 minutes to ensure all ingredients are fully dissolved.

Step 3: Add Phase B actives. Sprinkle Phase B ingredients slowly into the warm Phase A mixture while stirring at 400 rpm. This is critical: adding them too quickly causes localised clumping that is difficult to dissolve completely. Stir for 3–5 minutes until both actives are fully dissolved. The solution should be clear and colourless at this point.

Step 4: Cool to room temperature. Remove from heat and continue stirring as the formulation cools to 25°C. Do not rush this step — rapid cooling causes ingredient migration and can affect final clarity.

Step 5: Add Phase C preservative. Once the formulation has reached room temperature and is confirmed clear, add Euxyl PE 9010 at 1.0%. Stir at 500 rpm for 2 minutes. The preservative should be fully incorporated with no visible droplets.

Step 6: Measure and adjust pH. Using a calibrated pH meter, measure the formulation’s pH. Target range is 5.5–6.0. If the pH is below 5.5, add sodium hydroxide solution drop by drop, stirring between additions. If above 6.0, add citric acid solution drop by drop. Typical adjustment requires 0.2–0.5g of either solution.

Step 7: Packaging and QC. Transfer to an opaque 100ml PET bottle with a pump or mist closure. Label with batch number, date, pH reading, and concentration. Store at room temperature away from direct sunlight. Minimum stability data should include pH re-check at 24 hours and physical observation at week 1, 4, and 8.

Formulation Notes and Common Pitfalls

Why 3% tranexamic acid? Clinical studies supporting brightening efficacy span 2%–5%. Below 2%, the evidence for visible improvement weakens. Above 5%, the risk of skin irritation increases without proportional efficacy gains. Three percent represents the sweet spot for a leave-on toner format. If you are developing a wash-off format, 5% is more appropriate since contact time is shorter.

Niacinamide pairing. Combining tranexamic acid with niacinamide is one of the most evidence-backed brightening combinations in modern formulation science. Niacinamide (vitamin B3) works by blocking melanosome transfer from melanocytes to keratinocytes — a completely different mechanism from tranexamic acid’s prostaglandin inhibition. When used together at 3% each, they address the melanin production and transfer pathways simultaneously. A 2021 split-face clinical trial demonstrated that 3% tranexamic acid + 3% niacinamide combination achieved faster visible brightening than either active alone at 12 weeks.

The pH trap. The most common formulation mistake with tranexamic acid toners is ending up below pH 5.0. Many formulators use niacinamide at pH 5.0 for optimal antimicrobial preservation, but tranexamic acid at this pH has reduced efficacy. The 5.5–6.0 window is tight — plan for it from the start, not as an afterthought.

No vitamin C in the same formula. Ascorbic acid and tranexamic acid are both antioxidants, but they interact in solution in ways that can reduce efficacy of both actives. If you want to combine them, formulate as a two-step system (morning vitamin C serum, evening tranexamic acid toner) rather than in a single product.

Scale-Up Considerations

Moving from 200g lab batch to production-scale batches requires attention to mixing geometry, heat transfer uniformity, and particulate filtration. At 10kg scale or above, consider:

• Industrial overhead stirrer with variable speed control (200–600 rpm depending on batch viscosity)
• Jacketed stainless vessel for precise temperature control (no direct heat source)
• 0.45μm membrane filtration before filling to remove any suspended particles
• Preservation efficacy testing (PET) per ISO 11930 before commercial release

Summary: Key Takeaways

• Target pH 5.5–6.0 — outside this range, tranexamic acid loses potency and irritation risk rises
• 3% tranexamic acid + 3% niacinamide is the evidence-backed sweet spot for a brightening toner
• Never exceed 50°C when heating — both actives are heat-labile
• Pair with a broad-spectrum preservative; tranexamic acid has no antimicrobial properties of its own
• Scale-up requires filtration, PET testing, and temperature-controlled vessel mixing

Browse the complete AI Formula Guides for step-by-step recipes covering serums, moisturisers, ampoules, and masks — all backed by peer-reviewed clinical citations.